100 related articles for article (PubMed ID: 23313068)
1. CD30-positive cutaneous T-cell lymphoma and response to Brentuximab Vedotin: 2 illustrative cases.
Mody K; Wallace JS; Stearns DM; Bowers G; Lacy SR; Levy NB; Zug KA; Lansigan F
Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):319-23. PubMed ID: 23313068
[No Abstract] [Full Text] [Related]
2. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders.
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):10-1. PubMed ID: 24870875
[No Abstract] [Full Text] [Related]
4. Phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders.
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 5):12-4. PubMed ID: 24852791
[No Abstract] [Full Text] [Related]
5. Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression.
Saintes C; Saint-Jean M; Renaut JJ; Dréno B; Quéreux G
Br J Dermatol; 2015 Mar; 172(3):819-21. PubMed ID: 25113163
[No Abstract] [Full Text] [Related]
6. Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports.
Broccoli A; Derenzini E; Pellegrini C; Narducci R; Stefani G; Casadei B; Argnani L; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):493-5. PubMed ID: 23726017
[No Abstract] [Full Text] [Related]
7. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
Scarisbrick JJ
Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
[TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin for the treatment of CD30+ lymphomas.
Foyil KV; Bartlett NL
Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin.
Deng C; Pan B; O'Connor OA
Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab Beats Standard Therapies for CTCL.
Cancer Discov; 2017 Mar; 7(3):OF3. PubMed ID: 28119332
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin (replased/refractory Hodgkin lymphoma and CD30 positive non-Hodgkin lymphoma.
Kitahara H
Gan To Kagaku Ryoho; 2015 May; 42(5):550-2. PubMed ID: 26054088
[No Abstract] [Full Text] [Related]
14. CD30-targeted antibody therapy.
Younes A
Curr Opin Oncol; 2011 Nov; 23(6):587-93. PubMed ID: 21986847
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells.
Ansell SM
Expert Opin Investig Drugs; 2011 Jan; 20(1):99-105. PubMed ID: 21121873
[TBL] [Abstract][Full Text] [Related]
16. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies.
Fanale MA; Forero-Torres A; Rosenblatt JD; Advani RH; Franklin AR; Kennedy DA; Han TH; Sievers EL; Bartlett NL
Clin Cancer Res; 2012 Jan; 18(1):248-55. PubMed ID: 22080439
[TBL] [Abstract][Full Text] [Related]
17. Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms.
Fromm JR; McEarchern JA; Kennedy D; Thomas A; Shustov AR; Gopal AK
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):280-3. PubMed ID: 22542449
[No Abstract] [Full Text] [Related]
18. Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: a single-centre retrospective review.
Henderson Berg MH; Davison K; Popradi G
Br J Dermatol; 2022 Feb; 186(2):379-381. PubMed ID: 34608632
[No Abstract] [Full Text] [Related]
19. Brentuximab vedotin in CD30
Stranzenbach R; Dippel E; Schlaak M; Stadler R
Br J Dermatol; 2017 Dec; 177(6):1503-1509. PubMed ID: 28703284
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]